Low-dose aclarubicin in blastic transformation of essential thrombocythemia
- 1 May 1991
- journal article
- case report
- Published by Springer Nature in Annals of Hematology
- Vol. 62 (5) , 194-195
- https://doi.org/10.1007/bf01703149
Abstract
We attempted treatment with low-dose aclarubicin (ACR), a new anthracycline, in a 66-year-old man with blastic transformation of essential thrombocythemia (ET). Two courses of ACR (20 mg/day x 7 days) were given intravenously. He showed a good response to this therapy without severe side effects. He has since maintained a state of prolonged remission. These observations indicate that low-dose ACR may be beneficial for management of the blastic transformation of ET.Keywords
This publication has 8 references indexed in Scilit:
- Beneficial Treatment with Methyl 6-[3-(2-chloroethyl)-3-nitrosoureido]-6-deoxy-alpha-D-glucopyranoside in a Patient with Primary MyelofibrosisActa Haematologica, 1991
- Treatment of myelodysplastic syndrome and atypical leukemia with low-dose aclarubicinLeukemia Research, 1990
- Phase II Study of Aclarubicin in Acute Myeloblastic LeukemiaAmerican Journal of Clinical Oncology, 1987
- Essential thrombocythemias. Clinical evolutionary and biological dataCancer, 1986
- Essential Thrombocythemia and Leukemic TransformationMedicine, 1986
- Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group.1986
- Possible differentiation of human acute myeloblastic leukemia cells by daily and intermittent administration of aclacinomycin-ALeukemia Research, 1983
- New antitumor antibiotics, aclacinomycins A and B.The Journal of Antibiotics, 1975